Dynavax Technologies (DVAX) to Release Earnings on Wednesday

Dynavax Technologies (NASDAQ:DVAX) will be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Dynavax Technologies to post earnings of ($0.04) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Dynavax Technologies Trading Up 0.3 %

NASDAQ DVAX opened at $11.37 on Wednesday. The company’s fifty day simple moving average is $12.19 and its 200-day simple moving average is $13.13. Dynavax Technologies has a 52 week low of $10.06 and a 52 week high of $15.15. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. The stock has a market cap of $1.49 billion, a P/E ratio of -189.47 and a beta of 1.26.

Insider Transactions at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of Dynavax Technologies stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.98% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on DVAX shares. The Goldman Sachs Group started coverage on Dynavax Technologies in a research note on Thursday, February 1st. They set a “neutral” rating and a $20.00 target price for the company. William Blair reissued an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 23rd. Finally, StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Dynavax Technologies has an average rating of “Moderate Buy” and an average target price of $25.00.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.